Managing asthma in the era of biological therapies

Philip G Bardin, David Price, Pascal Chanez, Marc Humbert, Arnaud Bourdin

Research output: Contribution to journalComment/debate

3 Citations (Scopus)

Abstract

Asthma treatments have been remarkably successful at controlling symptoms. Up to 75% of people with asthma can achieve adequate asthma control on inhaled corticosteroids (ICS) with or without long-acting β2-agonists (LABA).1 But real-life studies have been sobering, indicating that full asthma control is only attained in about 30–40% of people with asthma.2. Many patients retain impairment of lung function and poor quality of life.3 Suboptimal asthma control might occur for various reasons, but there is consensus that poor adherence with asthma medications is a cardinal cause.3 Studies have suggested that asthmatics are especially prone to lapse treatment during asymptomatic periods when having to take regular treatment interferes with their lifestyle. Patients also have concerns about long-term side-effects of ICS, and many choose to live with persistent asthma symptoms. Finally, since asthma is a disease characterised by chronic airway inflammation with variable airflow limitation and unpredictable symptoms, treatment often requires frequent adjustment to achieve total control of chronic asthma. This aim might only be possible to attain in a small proportion of patients.
Original languageEnglish
Pages (from-to)376-378
Number of pages3
JournalThe Lancet. Respiratory medicine
Volume5
Issue number5
Early online date24 Apr 2017
DOIs
Publication statusPublished - May 2017

Fingerprint

Biological Therapy
Asthma
Adrenal Cortex Hormones
Social Adjustment
Therapeutics
Life Style
Consensus
Chronic Disease
Inflammation
Lung

Keywords

  • Journal Article

Cite this

Managing asthma in the era of biological therapies. / Bardin, Philip G; Price, David; Chanez, Pascal; Humbert, Marc; Bourdin, Arnaud.

In: The Lancet. Respiratory medicine, Vol. 5, No. 5, 05.2017, p. 376-378.

Research output: Contribution to journalComment/debate

Bardin, Philip G ; Price, David ; Chanez, Pascal ; Humbert, Marc ; Bourdin, Arnaud. / Managing asthma in the era of biological therapies. In: The Lancet. Respiratory medicine. 2017 ; Vol. 5, No. 5. pp. 376-378.
@article{ba77e66269a0446785b076bfee72eaf3,
title = "Managing asthma in the era of biological therapies",
abstract = "Asthma treatments have been remarkably successful at controlling symptoms. Up to 75{\%} of people with asthma can achieve adequate asthma control on inhaled corticosteroids (ICS) with or without long-acting β2-agonists (LABA).1 But real-life studies have been sobering, indicating that full asthma control is only attained in about 30–40{\%} of people with asthma.2. Many patients retain impairment of lung function and poor quality of life.3 Suboptimal asthma control might occur for various reasons, but there is consensus that poor adherence with asthma medications is a cardinal cause.3 Studies have suggested that asthmatics are especially prone to lapse treatment during asymptomatic periods when having to take regular treatment interferes with their lifestyle. Patients also have concerns about long-term side-effects of ICS, and many choose to live with persistent asthma symptoms. Finally, since asthma is a disease characterised by chronic airway inflammation with variable airflow limitation and unpredictable symptoms, treatment often requires frequent adjustment to achieve total control of chronic asthma. This aim might only be possible to attain in a small proportion of patients.",
keywords = "Journal Article",
author = "Bardin, {Philip G} and David Price and Pascal Chanez and Marc Humbert and Arnaud Bourdin",
year = "2017",
month = "5",
doi = "10.1016/S2213-2600(17)30124-8",
language = "English",
volume = "5",
pages = "376--378",
journal = "The Lancet. Respiratory medicine",
issn = "2213-2600",
publisher = "Elsevier Limited",
number = "5",

}

TY - JOUR

T1 - Managing asthma in the era of biological therapies

AU - Bardin, Philip G

AU - Price, David

AU - Chanez, Pascal

AU - Humbert, Marc

AU - Bourdin, Arnaud

PY - 2017/5

Y1 - 2017/5

N2 - Asthma treatments have been remarkably successful at controlling symptoms. Up to 75% of people with asthma can achieve adequate asthma control on inhaled corticosteroids (ICS) with or without long-acting β2-agonists (LABA).1 But real-life studies have been sobering, indicating that full asthma control is only attained in about 30–40% of people with asthma.2. Many patients retain impairment of lung function and poor quality of life.3 Suboptimal asthma control might occur for various reasons, but there is consensus that poor adherence with asthma medications is a cardinal cause.3 Studies have suggested that asthmatics are especially prone to lapse treatment during asymptomatic periods when having to take regular treatment interferes with their lifestyle. Patients also have concerns about long-term side-effects of ICS, and many choose to live with persistent asthma symptoms. Finally, since asthma is a disease characterised by chronic airway inflammation with variable airflow limitation and unpredictable symptoms, treatment often requires frequent adjustment to achieve total control of chronic asthma. This aim might only be possible to attain in a small proportion of patients.

AB - Asthma treatments have been remarkably successful at controlling symptoms. Up to 75% of people with asthma can achieve adequate asthma control on inhaled corticosteroids (ICS) with or without long-acting β2-agonists (LABA).1 But real-life studies have been sobering, indicating that full asthma control is only attained in about 30–40% of people with asthma.2. Many patients retain impairment of lung function and poor quality of life.3 Suboptimal asthma control might occur for various reasons, but there is consensus that poor adherence with asthma medications is a cardinal cause.3 Studies have suggested that asthmatics are especially prone to lapse treatment during asymptomatic periods when having to take regular treatment interferes with their lifestyle. Patients also have concerns about long-term side-effects of ICS, and many choose to live with persistent asthma symptoms. Finally, since asthma is a disease characterised by chronic airway inflammation with variable airflow limitation and unpredictable symptoms, treatment often requires frequent adjustment to achieve total control of chronic asthma. This aim might only be possible to attain in a small proportion of patients.

KW - Journal Article

U2 - 10.1016/S2213-2600(17)30124-8

DO - 10.1016/S2213-2600(17)30124-8

M3 - Comment/debate

VL - 5

SP - 376

EP - 378

JO - The Lancet. Respiratory medicine

JF - The Lancet. Respiratory medicine

SN - 2213-2600

IS - 5

ER -